全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Two Cases of Crohn’s Disease Presenting as Granulomatous Gastritis

DOI: 10.4236/oalib.1113502, PP. 1-7

Keywords: Crohn’s Disease, Granulomatous Gastritis, Corticosteroids, Infliximab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Granulomatous gastritis is an uncommon histological finding characterized by the presence of granulomas in the gastric mucosa. While granulomatous inflammation in the stomach can be attributed to a variety of causes, one rare but possible cause is Crohn’s disease. Crohn’s disease (CD) is a chronic inflammatory disorder primarily affecting the gastrointestinal tract, typically involving the terminal ileum and colon. However, isolated gastric involvement is rare and can create diagnostic difficulties. Patients with gastric Crohn’s disease may present with symptoms like peptic ulcer disease, including epigastric pain, nausea, vomiting, and potential gastric outlet obstruction. Endoscopy may reveal mucosal irregularities, ulcers, and strictures and the histology of Biopsies showing non-caseating granulomas is suggestive, though not pathognomonic, of Crohn’s disease. To confirm the diagnosis, other causes such as infection, sarcoidosis, and other potential causes of granulomas should be ruled out. Aim: The primary objective of this study is to elucidate the clinical presentation, diagnostic challenges, and management strategies associated with rare cases of granulomatous gastritis as the initial manifestation of Crohn’s disease. Case Presentation: We report two cases of Crohn’s disease initially manifesting as granulomatous gastritis, an uncommon presentation that underscores the need for a thorough differential diagnosis when encountering granulomatous inflammation in the stomach. The clinical presentation of the two patients was not specific (epigastric pain, nausea, and weight loss). The esophagogastroduodenoscopy revealed in the two cases an erythematous and nodular gastric mucosa of the antrum and the fundus. The histopathological analysis demonstrated non-caseating granulomas. The secondary etiologies of granulomatous gastritis were ruled out and an ileo-colonoscopy was performed for the two patients. The two patients were initially treated with corticosteroids, to which they exhibited a primary response, and were subsequently placed on maintenance therapy. Conclusion: Gastric Crohn’s disease, while rare, is an established clinical and pathological entity. Isolated granulomatous gastritis can serve as an initial indicator of Crohn’s disease; however, it alone is insufficient for a definitive diagnosis. A presumptive clinical diagnosis becomes more reliable when typical lesions are identified in the ileum or colon, supported by radiologic and endoscopic evaluations. Importantly, as demonstrated in our patients, histological confirmation via endoscopic biopsy can solidify the diagnosis.

References

[1]  Gajendran, M., Loganathan, P., et al. (2025) A Comprehensive Review and Update on Crohn’s Disease. https://www.sciencedirect.com/science/article/abs/pii/S0011502917301530?via%3Dihub
[2]  Magro, F., Rodrigues-Pinto, E., Coelho, R., Andrade, P., Santos-Antunes, J., Lopes, S., et al. (2014) Is It Possible to Change Phenotype Progression in Crohn’s Disease in the Era of Immunomodulators? Predictive Factors of Phenotype Progression. American Journal of Gastroenterology, 109, 1026-1036. https://doi.org/10.1038/ajg.2014.97
[3]  Horjus Talabur Horje, C.S., Meijer, J., Rovers, L., van Lochem, E.G., Groenen, M.J.M. and Wahab, P.J. (2016) Prevalence of Upper Gastrointestinal Le-sions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 22, 1896-1901. https://doi.org/10.1097/mib.0000000000000786
[4]  Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J.O., et al. (2016) 3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn’s and Colitis, 11, 3-25. https://doi.org/10.1093/ecco-jcc/jjw168
[5]  Kővári, B. and Pai, R.K. (2021) Upper Gastrointestinal Tract Involvement in Inflammatory Bowel Diseases: Histologic Clues and Pitfalls. Advances in Anatomic Pathology, 29, 2-14. https://doi.org/10.1097/pap.0000000000000311
[6]  Pimentel, A.M., Rocha, R. and Santana, G.O. (2019) Crohn’s Dis-ease of Esophagus, Stomach and Duodenum. World Journal of Gastrointestinal Pharmacology and Therapeutics, 10, 35-49. https://doi.org/10.4292/wjgpt.v10.i2.35
[7]  Schwartzberg, D.M., Brandstetter, S. and Grucela, A.L. (2019) Crohn’s Disease of the Esophagus, Duodenum, and Stomach. Clinics in Colon and Rectal Surgery, 32, 231-242. https://doi.org/10.1055/s-0039-1683850
[8]  Harpaz, N. and Polydorides, A.D. (2020) Upper Gastrointestinal Manifes-tations of Inflammatory Bowel Disease. Surgical Pathology Clinics, 13, 413-430. https://doi.org/10.1016/j.path.2020.05.003
[9]  Greenstein, A.J., Present, D.H., Sachar, D.B., Slater, G., Heimann, T., Lachman, P., et al. (1989) Gastric Fistulas in Crohn’s Disease. Diseases of the Colon & Rectum, 32, 888-892. https://doi.org/10.1007/bf02554563
[10]  Dancygier, H. and Frick, B. (1992) Crohn’s Disease of the Upper Gastrointes-tinal Tract. Endoscopy, 24, 555-558. https://doi.org/10.1055/s-2007-1010544
[11]  Fielding, J.F., Toye, D.K.M., Beton, D.C. and Cooke, W.T. (1970) Crohn’s Disease of the Stomach and Duodenum. Gut, 11, 1001-1006. https://doi.org/10.1136/gut.11.12.1001
[12]  Goyal, J., Khan, A., Goel, A. and Weber, F. (2014) Isolated Gastroduodenal Crohn’s Disease in a Septuagenarian Man. Endoscopy, 46, E167-E168. https://doi.org/10.1055/s-0034-1365096
[13]  Mottet, C., Juillerat, P., Gonvers, J., Michetti, P., Burnand, B., Vader, J., et al. (2005) Treatment of Gastroduodenal Crohn’s Disease. Digestion, 71, 37-40. https://doi.org/10.1159/000083871
[14]  Rodríguez-Grau, M.D.C., Chaparro, M., Díaz, R. and Gisbert, J.P. (2014) Infliximab en el tratamiento de la enfermedad de Crohn gastroduodenal resistente. Gastroenterología y Hepatología, 37, 21-22. https://doi.org/10.1016/j.gastrohep.2013.06.008
[15]  Odashima, M., Otaka, M., Jin, M., Horikawa, Y., Matsu-hashi, T., Ohba, R., et al. (2006) Successful Treatment of Refractory Duodenal Crohn’s Disease with Infliximab. Digestive Diseases and Sciences, 52, 31-32. https://doi.org/10.1007/s10620-006-9585-3
[16]  Hanauer, S.B., Feagan, B.G., Lich-tenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., et al. (2002) Maintenance Infliximab for Crohn’s Disease: The AC-CENT I Randomised Trial. The Lancet, 359, 1541-1549. https://doi.org/10.1016/s0140-6736(02)08512-4
[17]  Gaggar, S., Scott, J. and Thompson, N. (2012) Pyloric Stenosis Associated Crohn’s Disease Responding to Adalimumab Therapy. World Journal of Gastrointestinal Pharmacology and Therapeutics, 3, 97-99. https://doi.org/10.4292/wjgpt.v3.i6.97
[18]  Tursi, A. (2011) Duodenal Crohn’s Disease Successfully Treated with Ada-limumab. Endoscopy, 43, E22. https://doi.org/10.1055/s-0030-1255893

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133